Impax Laboratories (IPXL) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Impax Laboratories (IPXL) PT Lifted to $49 at Guggenheim Post Q4
February 24, 2015 10:34 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Impax Laboratories (NASDAQ: IPXL) to $49.00 (from $40.00) following better-than-expected Q4 results.
Chen commented, "Post 4Q14 beat, we remain positive on IPXL because it continues to exceed expectations despite... More
